Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.6.99.5 (
NADH dehydrogenase
)
2,135
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Deguelin, a plant-derived rotenoid, mediates potent chemopreventive responses through transcriptional regulation of phorbol ester-induced
ornithine decarboxylase
(
ODC
) activity. To explore the mechanism of this effect, the activity of this compound was evaluated with a number of model systems. Using cultured mouse epidermal 308 cells, the steady-state levels of both 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced
ODC
mRNA and c-fos were decreased by treatment with deguelin.
ODC
activity was also inhibited by bullatacin and various antimitotic agents (podophyllotoxin, vinblastine, and colchicine), but only deguelin and bullatacin were active as inhibitors of
ODC
levels in a TPA-independent c-Myc-mediated induction system using cultured BALB/c c-MycER cells. These results suggest that antimicrotubule effects, as mediated by rotenone, for example, are not responsible for inhibitory activity facilitated by deguelin. This was confirmed by use of an in vitro model of tubulin polymerization in which deguelin and a variety of other rotenoids were investigated and found to be inactive. As anticipated, however,
NADH dehydrogenase
was inhibited by these rotenoids. Moreover, inhibition of this enzyme correlated with a rapid depletion of ATP levels and potential to inhibit either TPA- or c-Myc-induced
ODC
activity. It therefore seems that deguelin-mediated interference with transient requirements for elevated energy can inhibit the induction of
ODC
activity and thereby yield a cancer chemopreventive response.
...
PMID:Regulation of ornithine decarboxylase induction by deguelin, a natural product cancer chemopreventive agent. 927 9